Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akebia Therapeutics, Inc. AKBA

Healthcare  —  Drug Manufacturers Specialty & Generic
0.90 (0.02) (2.17%) as of 25 Sep
Market cap
$254.7M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Akebia Therapeutics, Inc. (AKBA) Business Profile

Updated before January 2025

Company Overview

Akebia Therapeutics, Inc. (NASDAQ: AKBA) is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with kidney disease. Founded in 2007 and headquartered in Cambridge, Massachusetts, Akebia has established itself as a leader in the nephrology space. The company was co-founded by Joseph Gardner, who envisioned creating novel treatments for chronic kidney disease (CKD) and related conditions. Today, Akebia is led by John P. Butler, who serves as the President and Chief Executive Officer. Under his leadership, the company has expanded its portfolio and strengthened its position in the global market.

Akebia’s mission is to improve the lives of people impacted by kidney disease through the development of innovative therapies. The company operates with a patient-centric approach, focusing on addressing unmet medical needs in nephrology.

Core Business Segments

Akebia Therapeutics focuses on developing and commercializing products that address the needs of patients with kidney disease. Its core business segments include the following:

1. HIF-PHI Platform

Akebia’s lead product candidate is vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). Vadadustat is designed to treat anemia due to chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patients. The drug works by mimicking the body’s natural response to low oxygen levels, stimulating the production of erythropoietin and improving iron mobilization.

2. Commercial Products

Akebia markets and distributes Auryxia® (ferric citrate), an FDA-approved oral medication used to control serum phosphorus levels in adult patients with CKD on dialysis. Auryxia is also approved for the treatment of iron deficiency anemia in adult patients with CKD who are not on dialysis. This dual indication makes Auryxia a critical product in Akebia’s portfolio.

3. Research and Development (R&D)

Akebia invests heavily in R&D to expand its pipeline of innovative therapies. The company is exploring additional indications for vadadustat and other potential treatments for kidney-related conditions. Its robust R&D efforts aim to address gaps in the nephrology market and improve patient outcomes.

Business Model

Akebia Therapeutics operates a hybrid business model that combines product development, commercialization, and strategic partnerships. The company generates revenue through the following channels:

  • Product Sales: Revenue from the sale of Auryxia® contributes significantly to Akebia’s financial performance. The company leverages its established distribution network to ensure broad access to its products.
  • Collaborations and Licensing Agreements: Akebia partners with leading pharmaceutical companies to co-develop and commercialize its products. For example, the company has entered into agreements with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of vadadustat in the U.S., Europe, and other regions.
  • Royalties and Milestone Payments: Akebia receives royalties and milestone payments from its partners based on the achievement of specific regulatory and commercial milestones.

The company’s integrated approach allows it to maximize the value of its products while addressing the needs of patients and healthcare providers.

Strategic Direction

Akebia Therapeutics is focused on achieving long-term growth and sustainability through the following strategic initiatives:

  • Expanding the Vadadustat Franchise: Akebia aims to secure regulatory approvals for vadadustat in additional markets, including Europe and Asia. The company is also exploring new indications for the drug to broaden its therapeutic applications.
  • Enhancing Commercial Capabilities: Akebia is investing in its sales and marketing infrastructure to drive the adoption of Auryxia® and future products. The company is also exploring opportunities to expand its product portfolio through acquisitions and partnerships.
  • Commitment to Sustainability: Akebia is dedicated to minimizing its environmental impact and promoting sustainable practices across its operations. The company is actively working to reduce waste, conserve resources, and support community health initiatives.
  • Innovation in Nephrology: Akebia continues to invest in R&D to develop next-generation therapies for kidney disease. The company is leveraging its expertise in HIF biology to identify new drug candidates and advance its pipeline.

Competitive Landscape

Akebia Therapeutics operates in a highly competitive market, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Amgen Inc.: A leader in nephrology, Amgen offers products such as Aranesp® and Epogen® for the treatment of anemia in CKD patients.
  • FibroGen, Inc.: FibroGen is a direct competitor in the HIF-PHI space, with its product roxadustat approved in several markets for the treatment of anemia in CKD.
  • Keryx Biopharmaceuticals: Now part of Akebia, Keryx previously competed with Auryxia® in the CKD market.
  • Other Biotech Firms: Smaller companies developing novel therapies for kidney disease also pose a competitive threat.

Akebia differentiates itself through its focus on innovation, patient-centric approach, and strategic partnerships.

Risk Factors

Akebia Therapeutics faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The approval process for new drugs is complex and uncertain. Delays or rejections by regulatory authorities could hinder the commercialization of vadadustat and other pipeline products.
  • Market Dependence: Akebia relies heavily on the success of Auryxia® and vadadustat. Any decline in sales or market share could adversely affect the company’s revenue.
  • Supply Chain Disruptions: The company depends on third-party manufacturers and suppliers for the production of its products. Disruptions in the supply chain could impact product availability and sales.
  • Competition: Intense competition in the nephrology market could limit Akebia’s growth potential and pricing power.
  • Financial Constraints: As a biopharmaceutical company, Akebia requires significant capital to fund its R&D and commercialization efforts. Limited access to funding could impede its growth.

Recent Developments

  • Regulatory Updates: In 2023, Akebia announced progress in its regulatory submissions for vadadustat in Europe and other regions. The company is working closely with regulatory authorities to address any concerns and secure approvals.
  • Partnerships: Akebia expanded its collaboration with Otsuka Pharmaceutical Co., Ltd., strengthening its global commercialization strategy for vadadustat.
  • Pipeline Advancements: The company reported positive clinical trial results for vadadustat, demonstrating its efficacy and safety in treating anemia due to CKD.
  • Corporate Initiatives: Akebia implemented cost-saving measures to improve operational efficiency and support its long-term growth objectives.

Investment Considerations

Strengths:

  • Strong focus on nephrology, a growing therapeutic area with significant unmet needs.
  • Established product portfolio, including Auryxia®, with dual indications.
  • Promising pipeline led by vadadustat, a potential blockbuster drug.
  • Strategic partnerships with leading pharmaceutical companies.
  • Commitment to innovation and sustainability.

Risks:

  • Heavy reliance on a limited number of products for revenue generation.
  • Regulatory and competitive challenges in the nephrology market.
  • Financial risks associated with high R&D and commercialization costs.
  • Potential supply chain disruptions and market volatility.

Conclusion

Akebia Therapeutics, Inc. is a leading player in the nephrology market, driven by its commitment to innovation and patient-centric approach. With a strong product portfolio, promising pipeline, and strategic partnerships, the company is well-positioned for growth. However, it faces challenges such as regulatory hurdles, competition, and financial constraints. Investors should weigh these factors carefully when considering Akebia as a potential investment. Looking ahead, Akebia’s focus on expanding its vadadustat franchise, enhancing commercial capabilities, and driving innovation in nephrology will be key to its success in the global market.